Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations

Journal of Clinical Pharmacology

Volumn 52, Issue 5, 2012, Pages 757-765

  Gerrits, Mireille G F ^a   De Greef, Rik ^a   Dogterom, Peter ^a   Peeters, Pierre A M ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Asenapine; glucuronidation; interactions; metabolites; pharmacokinetics; valproate

Indexed keywords

ASENAPINE; GLUCURONIDE; PLACEBO; VALPROIC ACID;

ABDOMINAL DISCOMFORT; ADULT; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRADYCARDIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FLATUKENCE; FLATULENCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; ORAL PARESTHESIA; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; XEROSTOMIA;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; CROSS-OVER STUDIES; DEALKYLATION; DRUG INTERACTIONS; GLUCURONIDES; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; VALPROIC ACID; YOUNG ADULT;

EID: 84860309840     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011404028     Document Type: Article

References (24)

1. Whitehouse Station, NJ: Schering Corporation ; 2010:
2. European Medicines Agency. Sycrest (asenapine). http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/001177/human-med-001379. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124& jsenabled=true. Accessed September 28, 2010.
3. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 ; 23 (1). 65-73
4. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010 ; 30: 106-115
5. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007 ; 68: 1492-1500 (Pubitemid 350073395)
6. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010 ; 43: 138-146
7. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010 ; 122: 27-38
8. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009 ; 11: 673-686
9. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009 ; 11: 815-826
10. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek T, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010 ; 126: 358-365
11. van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, et al. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab Dispos. 2011 ; 39 (4). 580-590
12. Summit, NJ: Merck ; 2009:
13. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull. 2007 ; 40: 77-97
14. Dogterom P, Hulskotte E, Gerrits M, et al. Asenapine pharmacokinetics: influence of cytochrome P450 modulators and UDP-glucuronyltransferase inhibition. Eur Neuropsychopharmacol. 2008 ; 18: S452 - S453
15. Bowden CL. Valproate. Bipolar Disord. 2003 ; 5: 189-202 (Pubitemid 36752628)
16. DeVane CL. Pharmacokinetics drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003 ; 37: 25-42
17. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 ; 106: 97-132 (Pubitemid 40386722)
18. Samara EE, Grannemann RG, Witt GF, Cavanaugh JH. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol. 1997 ; 37: 442-450 (Pubitemid 27215072)
19. In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, MD: US Food and Drug Administration ; 1999:
20. de Boer T, Meulman E, Meijering H, et al. Quantification of asenapine and three major metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects. Biomedical Chromatography.. 2011 ;:
21. Prohn M, de Greef HJMM, Chapel S, Kerbusch T. Population pharmacokinetics of asenapine in patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2009 ; 19: S542 - S543
22. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther. 1996 ; 60: 145-156 (Pubitemid 26348229)
23. Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol. 2009 ; 5: 539-551
24. Calabrese JR, Stet L, Kotari H, et al. Asenapine as adjunctive treatment for bipolar mania: a placebo-controlled 12-week study and 40-week extension. Eur Psychiatr. 2010 ; 25: 1447